Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 42 for:    reach2hd
Previous Study | Return to List | Next Study

Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease (Reach2HD)

This study has been completed.
Information provided by (Responsible Party):
Prana Biotechnology Limited Identifier:
First received: April 18, 2012
Last updated: February 9, 2014
Last verified: February 2014

April 18, 2012
February 9, 2014
April 2012
July 2013   (final data collection date for primary outcome measure)
Safety and Tolerability of PBT2 in patients with HD by measuring Frequency of Adverse Events. [ Time Frame: 26 weeks ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01590888 on Archive Site
  • Change from Baseline in Cognitive Test Battery [ Time Frame: 12 and 26 weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in Motor Function [ Time Frame: 12 and 26 weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in Functional Abilities [ Time Frame: 12 and 26 weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in Behaviour [ Time Frame: 12 and 26 weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in Subject and Investigator Global Assessments [ Time Frame: 12 and 26 weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in plasma and urine Biomarkers [ Time Frame: 12 and 26 weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in Brain Volumes and Function (MRI) [ Time Frame: 12 and 26 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease

Huntington disease (HD) is an inherited neurodegenerative disease which affects over 30,000 people in both the United States and Australia. HD is characterized by brain cell death that usually begins between the ages of 30 to 50, and results in motor, cognitive and behavioral signs and symptoms. While there are medications to help relieve some of the disease symptoms, there is no known treatment to address the cognitive impairment associated with HD.

Normally occurring metals in the brain play a significant role in diseases such as Alzheimer disease and more recently, HD. PBT2 is a drug designed to interrupt interactions between these biological metals and target proteins in the brain, to prevent deterioration of brain cells. PBT2, has shown in animal models, and as well as in a small group of patients with Alzheimer's disease, it may improve cognition. There is some indication in animal models of HD, that the drug may improve motor function and control and reduce the amount of brain cell degeneration. Based on these results, this clinical trial is investigating whether the drug will have similar effects with HD patients.

PBT2-203 will evaluate how safe and well tolerated PBT2 is at a dose of 100 mg or 250 mg a day administered as oral daily capsules compared to a placebo over six months treatment period. The trial will also measure whether there is an effect on cognitive abilities as well as other HD symptoms including motor and overall functioning of individuals with HD.

Not Provided
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Huntington Disease
  • Drug: PBT2
    250mg capsules administered orally once per day for 26 weeks
  • Drug: PBT2
    100mg capsules administered orally once per day for 26 weeks
  • Drug: Placebo
    Matching capsules administered orally once per day for 26 weeks
  • Experimental: PBT2 250mg
    Intervention: Drug: PBT2
  • Experimental: PBT2 100mg
    Intervention: Drug: PBT2
  • Placebo Comparator: Sugar pill
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2014
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients who:

    1. Provide signed informed consent in accordance with local regulations.
    2. Have Huntington disease including clinical features of HD and a CAG repeat number ≥ 36.
    3. Have a Total Functional Capacity between 6 and 13, inclusive.
    4. Have cognitive impairment as demonstrated by a MoCA score of ≥ 12.
    5. Are ≥ 25 years of age.
    6. If taking tetrabenazine, have been on a stable dose for at least 3 months.
    7. If female, are either a) of childbearing potential and compliant in using adequate birth control or b) not of childbearing potential.
    8. If male, is either a) of reproductive potential and compliant in using adequate birth control or b) not of reproductive potential.
    9. Have a study partner who is willing to provide consent and spends on average at least two hours a day for at least four days a week with the patient, is fluent in the English language, and who agrees to attend certain study visits and provide accurate information about the patient.
    10. Are able to swallow oral capsules.
    11. Are fluent in the English language for the administration of rating scales and have sufficient visual, hearing and motor skills to complete procedures.

      Exclusion Criteria:

  • Patients who:

    1. Have an allergy to PBT2 or its excipients.
    2. Have other known primary neurodegenerative disorders associated with dementia.
    3. Have known dementia syndromes due to non-primary CNS disease.
    4. Have another condition that in the investigator's judgment is resulting in clinically significant cognitive impairment.
    5. In the opinion of the investigator, have any clinically significant uncontrolled medical or psychiatric illness, including history of seizures.
    6. Have clinically significant cardiovascular, hepatic, renal, pulmonary, metabolic or endocrine disease that, in the opinion of the investigator, would interfere with an individual's participation in the study.
    7. Have a calculated creatinine clearance at Screening of <50mL/min.
    8. Have a history of malignancy diagnosed within 2 years of Screening.
    9. Are pregnant or lactating females.
25 Years and older
Contact information is only displayed when the study is recruiting subjects
United States,   Australia
Prana Biotechnology Limited
Prana Biotechnology Limited
Not Provided
Principal Investigator: Ray Dorsey Johns Hopkins University
Prana Biotechnology Limited
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP